Remedent, Inc. (REMI)
USD 0.02
(0.0%)
USD 0.02
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 5.48 Million USD | -1.78% |
| 2023 | 5.58 Million USD | -19.57% |
| 2022 | 6.94 Million USD | -3.25% |
| 2021 | 7.18 Million USD | -4.36% |
| 2020 | 7.5 Million USD | -4.9% |
| 2019 | 7.89 Million USD | 45.2% |
| 2018 | 5.43 Million USD | 14.98% |
| 2017 | 4.72 Million USD | -17.06% |
| 2016 | 5.7 Million USD | 2.85% |
| 2015 | 5.54 Million USD | -10.11% |
| 2014 | 6.16 Million USD | -5.49% |
| 2013 | 6.52 Million USD | -6.29% |
| 2012 | 6.96 Million USD | -27.61% |
| 2011 | 9.62 Million USD | 21.27% |
| 2010 | 7.93 Million USD | -22.22% |
| 2009 | 10.2 Million USD | 37.03% |
| 2008 | 7.44 Million USD | 70.07% |
| 2007 | 4.37 Million USD | -13.53% |
| 2006 | 5.06 Million USD | 86.64% |
| 2005 | 2.71 Million USD | 25.28% |
| 2004 | 2.16 Million USD | 319.08% |
| 2003 | 516.67 Thousand USD | -99.93% |
| 2002 | 785.54 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q4 | 5.48 Million USD | -3.63% |
| 2024 FY | 5.48 Million USD | -1.78% |
| 2024 Q3 | 5.69 Million USD | 4.95% |
| 2024 Q2 | 5.42 Million USD | -1.28% |
| 2024 Q1 | 5.49 Million USD | -1.63% |
| 2023 Q4 | 5.58 Million USD | -5.93% |
| 2023 Q1 | 6.51 Million USD | 0.0% |
| 2023 FY | 5.58 Million USD | -19.57% |
| 2023 Q2 | 6.11 Million USD | -6.14% |
| 2023 Q3 | 5.94 Million USD | -2.82% |
| 2022 FY | 6.94 Million USD | -3.25% |
| 2021 Q3 | 7.56 Million USD | 1.18% |
| 2021 FY | 7.18 Million USD | -4.36% |
| 2021 Q2 | 7.47 Million USD | 0.17% |
| 2021 Q1 | 7.46 Million USD | -0.62% |
| 2020 Q2 | 7.92 Million USD | -0.08% |
| 2020 Q4 | 7.5 Million USD | -3.18% |
| 2020 FY | 7.5 Million USD | -4.9% |
| 2020 Q3 | 7.75 Million USD | -2.16% |
| 2020 Q1 | 7.93 Million USD | 0.47% |
| 2019 FY | 7.89 Million USD | 45.2% |
| 2019 Q1 | 5.27 Million USD | -2.91% |
| 2019 Q2 | 5.24 Million USD | -0.63% |
| 2019 Q3 | 5.12 Million USD | -2.3% |
| 2019 Q4 | 7.89 Million USD | 54.04% |
| 2018 Q4 | 5.43 Million USD | 3.31% |
| 2018 Q3 | 5.26 Million USD | 6.02% |
| 2018 FY | 5.43 Million USD | 14.98% |
| 2018 Q2 | 4.96 Million USD | 5.32% |
| 2018 Q1 | 4.71 Million USD | -0.33% |
| 2017 Q3 | 5.79 Million USD | 0.22% |
| 2017 Q1 | 5.71 Million USD | 0.18% |
| 2017 Q2 | 5.77 Million USD | 1.17% |
| 2017 FY | 4.72 Million USD | -17.06% |
| 2017 Q4 | 4.72 Million USD | -18.34% |
| 2016 Q3 | 5.74 Million USD | 0.83% |
| 2016 Q1 | 5.64 Million USD | 1.8% |
| 2016 Q2 | 5.69 Million USD | 0.87% |
| 2016 Q4 | 5.7 Million USD | -0.67% |
| 2016 FY | 5.7 Million USD | 2.85% |
| 2015 Q3 | 5.7 Million USD | -2.4% |
| 2015 FY | 5.54 Million USD | -10.11% |
| 2015 Q4 | 5.54 Million USD | -2.82% |
| 2015 Q1 | 6 Million USD | -2.67% |
| 2015 Q2 | 5.84 Million USD | -2.62% |
| 2014 Q1 | 6.21 Million USD | -4.78% |
| 2014 Q2 | 6.07 Million USD | -2.19% |
| 2014 Q3 | 6.28 Million USD | 3.38% |
| 2014 Q4 | 6.16 Million USD | -1.85% |
| 2014 FY | 6.16 Million USD | -5.49% |
| 2013 Q3 | 6.18 Million USD | -2.19% |
| 2013 Q2 | 6.32 Million USD | -0.26% |
| 2013 Q1 | 6.33 Million USD | -9.01% |
| 2013 FY | 6.52 Million USD | -6.29% |
| 2013 Q4 | 6.52 Million USD | 5.56% |
| 2012 FY | 6.96 Million USD | -27.61% |
| 2012 Q2 | 10.69 Million USD | 2.43% |
| 2012 Q3 | 7.14 Million USD | -33.23% |
| 2012 Q4 | 6.96 Million USD | -2.48% |
| 2012 Q1 | 10.44 Million USD | 8.53% |
| 2011 Q2 | 10.38 Million USD | 12.98% |
| 2011 FY | 9.62 Million USD | 21.27% |
| 2011 Q4 | 9.62 Million USD | -3.7% |
| 2011 Q3 | 9.99 Million USD | -3.79% |
| 2011 Q1 | 9.19 Million USD | 15.85% |
| 2010 FY | 7.93 Million USD | -22.22% |
| 2010 Q4 | 7.93 Million USD | -9.13% |
| 2010 Q1 | 10.17 Million USD | -0.26% |
| 2010 Q2 | 8.16 Million USD | -19.79% |
| 2010 Q3 | 8.73 Million USD | 6.99% |
| 2009 Q3 | 10.54 Million USD | 15.12% |
| 2009 FY | 10.2 Million USD | 37.03% |
| 2009 Q4 | 10.2 Million USD | -3.25% |
| 2009 Q2 | 9.16 Million USD | 15.51% |
| 2009 Q1 | 7.93 Million USD | 6.51% |
| 2008 Q3 | 7.27 Million USD | -6.36% |
| 2008 Q4 | 7.44 Million USD | 2.28% |
| 2008 Q2 | 7.77 Million USD | -27.83% |
| 2008 Q1 | 10.77 Million USD | 146.04% |
| 2008 FY | 7.44 Million USD | 70.07% |
| 2007 FY | 4.37 Million USD | -13.53% |
| 2007 Q4 | 4.37 Million USD | -3.37% |
| 2007 Q2 | 5.13 Million USD | 34.86% |
| 2007 Q3 | 4.53 Million USD | -11.8% |
| 2007 Q1 | 3.8 Million USD | -24.77% |
| 2006 Q3 | 5.35 Million USD | 10.01% |
| 2006 Q4 | 5.06 Million USD | -5.41% |
| 2006 Q2 | 4.86 Million USD | 94.96% |
| 2006 Q1 | 2.49 Million USD | -7.99% |
| 2006 FY | 5.06 Million USD | 86.64% |
| 2005 Q3 | 2.23 Million USD | 4.26% |
| 2005 Q2 | 2.14 Million USD | 40.29% |
| 2005 FY | 2.71 Million USD | 25.28% |
| 2005 Q1 | 1.52 Million USD | -29.5% |
| 2005 Q4 | 2.71 Million USD | 21.49% |
| 2004 Q3 | 1.73 Million USD | 44.48% |
| 2004 Q1 | 701.32 Thousand USD | 35.74% |
| 2004 FY | 2.16 Million USD | 319.08% |
| 2004 Q4 | 2.16 Million USD | 24.84% |
| 2004 Q2 | 1.2 Million USD | 71.18% |
| 2003 Q1 | 939.48 Thousand USD | 19.22% |
| 2003 Q2 | 779.33 Thousand USD | -17.05% |
| 2003 FY | 516.67 Thousand USD | -99.93% |
| 2003 Q4 | 516.67 Thousand USD | -44.58% |
| 2003 Q3 | 932.31 Thousand USD | 19.63% |
| 2002 Q3 | 358.83 Thousand USD | -30.34% |
| 2002 Q2 | 515.15 Thousand USD | 66.13% |
| 2002 Q1 | 310.08 Thousand USD | 85.77% |
| 2002 FY | 785.54 Million USD | 0.0% |
| 2002 Q4 | 788.04 Thousand USD | 119.61% |
| 2001 Q3 | 232.63 Thousand USD | -9.63% |
| 2001 Q2 | 257.41 Thousand USD | -7.73% |
| 2001 Q4 | 166.91 Thousand USD | -28.25% |
| 2001 Q1 | 278.96 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| American Medical Technologies Inc. | 1.83 Million USD | -198.632% |
| Ansell Limited | 3.23 Billion USD | 99.83% |
| Ansell Limited | 3.24 Billion USD | 99.831% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 488.98 Million USD | 98.877% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 300.36 Thousand USD | -1727.476% |
| Psykey, Inc. | 1.72 Million USD | -217.771% |
| ConvaTec Group Plc | 3.7 Billion USD | 99.852% |
| ConvaTec Group Plc | 3.71 Billion USD | 99.852% |
| Encision Inc. | 3.81 Million USD | -44.042% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | - USD | -Infinity% |
| Innovative MedTech Inc. | 651.88 Thousand USD | -742.031% |
| LifePoint, Inc. | 8.8 Million USD | 37.689% |
| Medite Cancer Diagnostics, Inc. | 15.95 Million USD | 65.599% |
| Paradigm Medical Industries, Inc. | 895 Thousand USD | -513.301% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Reflect Scientific, Inc. | 2.66 Million USD | -105.667% |
| SmileDirectClub, Inc. | 597.06 Million USD | 99.081% |
| Sector 10, Inc. | 1000.00 USD | -548804.3% |
| Shandong Weigao Group Medical Polymer Company Limited | 4.74 Billion USD | 99.884% |
| SheerVision, Inc. | 837.56 Thousand USD | -555.357% |
| United Health Products, Inc. | 284.64 Thousand USD | -1828.396% |
| Vasamed, Inc. | 1.6 Million USD | -243.013% |
| Wearable Health Solutions, Inc. | 223.17 Thousand USD | -2359.546% |
| Yubo International Biotech Limited | 2.34 Million USD | -133.72% |